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Introduction
Rheumatoid arthritis (RA), a systemic disease, is the most
common form of inflammatory arthritis [1]. The disorder has
a worldwide prevalence of about 1% and an annual inci-
dence of 3 per 10,000 adults [2,3]; it is more common in
women than in men [2]. RA is accompanied by significant
morbidity and mortality. Depending on the severity of the
disease at onset, the risk of disability can be as high as
33%, and mortality can be increased by as much as 52%,
frequently as a result of infection or circulatory disease [4].
As might be expected, patients with RA also have a signifi-
cant impairment in their quality of life (QOL) [5].
The ultimate goals of treatment are the prevention or
control of joint damage, the prevention of functional loss,
and the relief of pain [6]. With the earlier and more
aggressive use of disease-modifying anti-rheumatic drugs
(DMARDs) and with the introduction of the tumor necrosis
factor (TNF) antagonists during the past 5 years, the man-
agement of RA has changed markedly. Previously, treat-
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Abstract
Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid
arthritis (RA). Three agents currently available in the USA – infliximab, etanercept, and adalimumab –
have been designed to modify the biologic effects of TNF. Infliximab and adalimumab are monoclonal
antibodies, and etanercept is a soluble protein. The pharmacokinetic and pharmacodynamic properties
of each differs significantly from those of the others. All three agents are effective and safe, and can
improve the quality of life in patients with RA. Although no direct comparisons are available, clinical
trials provide evidence that can be used to evaluate the comparative efficacy of these agents.
Infliximab, in combination with methotrexate, has been shown to relieve the signs and symptoms of RA,
decrease total joint score progression, prevent joint erosions and joint-space narrowing, and improve
physical function for up to 2 years. Etanercept has been shown to relieve the signs and symptoms of
RA, decrease total joint score progression, and slow the rate of joint destruction, and might improve
physical function. Etanercept is approved with and without methotrexate for patients who have
demonstrated an incomplete response to therapy with methotrexate and other disease-modifying anti-
rheumatic drugs (DMARDs), as well as for first-line therapy in early RA, psoriatic arthritis, and juvenile
RA. Adalimumab relieves the signs and symptoms of RA with and without methotrexate and other
DMARDs, decreases total joint score progression, prevents joint erosions and joint-space narrowing in
combination with methotrexate, and might improve physical function. When selecting a TNF
antagonist, rheumatologists should weigh evidence and experience with specific agents before a
decision is made for use in therapy.
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ment was organized in a therapeutic pyramid, in which
conservative management with nonsteroidal anti-inflammatory
drugs was administered for several years, followed by the
addition of DMARDs in a slow and incremental fashion
once radiographic evidence of bony erosions appeared
[1]. Unfortunately, this approach was associated with
increased morbidity, lost productivity, decreased life
expectancy, and increased healthcare costs. Today, treat-
ment with DMARDs alone, or in combination, and with
TNF biologic response modifiers is initiated early in
patients with RA who are at an increased risk for progres-
sive disease [1,7,8]. The 2001 World Health Organization
Collaborating Centre consensus meeting on anti-cytokine
therapy guidelines identified appropriate patients eligible
for anti-cytokine therapy as patients with active RA who
have failed an adequate course of DMARD therapy [8]. In
these guidelines, unacceptable disease activity was
defined as five swollen joints plus an elevated acute-phase
response such as an erythrocyte sedimentation rate (ESR)
of more than 28 mm/h or a C-reactive protein (CRP) con-
centration of more than 20 mg/l, whereas adequate expo-
sure was defined as a course of methotrexate at a dose of
at least 20 mg/week for 3 months or a smaller dose if toxic-
ity is a limiting factor [8]. The international consensus
guidelines have provided useful additional evidence-based
recommendations [9,10].
Infliximab (Remicade®; Centocor, Inc., Malvern, PA, USA),
etanercept (Enbrel®; Immunex Corp, Seattle, WA, USA),
and adalimumab (Humira™; Abbott Laboratories, Abbott
Park, IL, USA) are designed to modulate the inflammatory
cascade of RA by binding TNF, thereby decreasing its
bioavailability. Various cytokines have been detected in the
synovial fluid of patients with RA, both pro-inflammatory
(namely TNF, interleukin-1 [IL-1], and IL-6) and anti-inflam-
matory (transforming growth factor-β and IL-10) [11]. With
several cytokines involved in the cytokine network of RA, it
was argued that the suppression of only one mediator in a
cytokine network might not be sufficient to control the
pathophysiologic process underlying the disease [11].
Early studies by Brennan and colleagues demonstrated
that in a synovial cell culture system the secondary synthe-
sis of IL-1 and other cytokines could be markedly reduced
by targeting TNF [11,12]. This led to more active research
in this direction. In summary, the role of TNF is based on
(1) its ability to degrade cartilage and bone in vitro, (2) its
arthritogenic properties in animal models, (3) the co-
localization of  its receptors in RA synovium and the
pannus–cartilage junction, and (4) its central role in regu-
lating the synthesis of IL-1 in cultured RA-derived synovial
cells [13,14].
Infliximab, etanercept, and adalimumab have undergone
extensive clinical trials that have shown them to be effica-
cious and safe. Although they share common properties
as TNF biologic response modifiers, these agents
possess distinct pharmacokinetic and pharmacodynamic
profiles. In the absence of any directly comparative trials,
this article seeks to place the various considerations of
their efficacy in perspective. It focuses on how these
agents have fared in terms of their effects on symptoms
(assessed by American College of Rheumatology [ACR]
response criteria), structure (based on erosion, joint-space
narrowing, and Sharp scores), and physical function/QOL
(based on standardized questionnaires such as the Health
Assessment Questionnaire [HAQ]).
Etanercept
Etanercept is a fusion protein consisting of the ligand-
binding portion of the human p75 TNF receptor plus the
Fc fragment of human IgG1 [15]. Etanercept has a termi-
nal half-life of 102 ± 30 hours [15]. The recommended
starting dose is 25 mg subcutaneously (s.c.) twice weekly,
with or without methotrexate [15].
In a multicenter, double-blind, placebo-controlled, phase II
trial, 180 patients with refractory RA were randomized to
one of four groups: etanercept 0.25, 2, or 16 mg/m2 s.c.,
or placebo twice weekly for 3 months [16]. The primary
efficacy measure was the percentage change in swollen
joint count, tender joint count, and total count of swollen
and tender joints from baseline to study end point
(3 months) [16]. The data were then analyzed to deter-
mine the number of patients who attained the ACR criteria
for 20% improvement (ACR20) and 50% improvement
(ACR50). ACR20 is defined as a 20% improvement in
tender and swollen joint counts and at least three of the
following disease activity variables: patient’s assessment
of pain, patient’s global assessment of disease activity,
physician’s global assessment of disease activity, patient’s
assessment of physical function, and ESR or CRP con-
centration [17]. Treatment with etanercept resulted in sig-
nificant dose-related reductions in disease activity. After
3 months, improvements in ACR20 criteria were demon-
strated in 75% of patients in the group with the highest
dose (16 mg/m2), compared with 14% of controls
(P < 0.001). Additionally, the mean percentage reduction
in the number of tender or swollen joints was significantly
greater in the etanercept 16 mg/m2 group than in the con-
trols (61% versus 25%, P < 0.001). There were no signifi-
cant safety issues. The authors concluded that
monotherapy with etanercept for 3 months is safe, well tol-
erated, and associated with clinical improvement in the
symptoms of RA.
Moreland and colleagues evaluated the efficacy of 10 mg
and 25 mg doses of etanercept by using the primary effi-
cacy end points of improvements in disease activity as
determined by ACR20 and ACR50 criteria at 3 and
6 months [18]. This randomized, placebo-controlled trial
involved 234 American and Canadian patients with activeS5
RA who had demonstrated an inadequate response to
DMARD therapy. The number of patients who attained the
ACR criteria for 70% improvement (ACR70) and changes
in scores for swollen and tender joints were also assessed
at the specified time intervals. Etanercept produced a sig-
nificant dose-related improvement in disease manifesta-
tion. At 3 months, a significantly greater percentage of
patients in the etanercept 25 mg group achieved ACR20
and ACR70 responses than did controls (62% versus
23%,  P < 0.001 [ACR20], and 41% versus 8%,
P < 0.001 [ACR50]) [18]. At 6 months, a significantly
greater percentage of patients who received etanercept
25 mg met the ACR20 and ACR50 criteria than did con-
trols (59% versus 11%, P < 0.001 [ACR20] and 40%
versus 5%, P < 0.001 [ACR50]) [18]. Similarly, improve-
ments in ACR20 and ACR50 scores were reported in a
significantly greater percentage of patients who received
etanercept 10 mg than controls (51% versus 11%,
P < 0.001 [ACR20] and 24% versus 5%, P < 0.001
[ACR50]). Other 6-month results showed that mean
counts of tender and swollen joints were significantly
reduced in the patients who received etanercept 25 mg
compared with controls (56% versus 6%, P < 0.05; 47%
versus 7%, P < 0.05, respectively) [18]. Finally, signifi-
cantly more etanercept-treated patients achieved an
ACR70 response than did controls. At 6 months, 15% of
patients in the etanercept 25 mg group, 9% of patients in
the etanercept 10 mg group, and 1% of patients in the
placebo group had achieved ACR70 response (P < 0.031
for each etanercept group compared with the placebo
group) [18]. Etanercept was well tolerated, and the inves-
tigators concluded that etanercept monotherapy could
safely provide rapid, significant, and sustained benefits in
patients with active RA.
The long-term efficacy and safety of etanercept monother-
apy in patients with DMARD-refractory RA have also been
demonstrated in open-label extension studies lasting up to
5 years [19,20]. Patients from a previous long-term safety
trial, in which etanercept monotherapy was investigated in
adults who had not responded satisfactorily to at least one
DMARD, have been followed for up to 4.3 years (median,
2.4 years) for a total of 1336 patient-years [19]. Results are
now available for 479 adult patients who received etaner-
cept as monotherapy for more than 1 year, 420 patients
who received the drug for more than 2 years, 164 patients
who received the drug for more than 3 years, and 12
patients who received the drug for more than 4 years [19].
Patients were evaluated by ACR criteria for disease activ-
ity. At 3.5 years, 69%, 50%, and 25% of patients had
achieved ACR20, ACR50, and ACR70 responses,
respectively [19]. Moreland and colleagues reported their
observations on the efficacy and safety of up to 5 years of
etanercept therapy in patients with RA on the basis of the
experience of participants in North American trials of etan-
ercept who decided to enroll in open-label extension
studies [20]. Data on long-term efficacy were available
from 159 patients who had been evaluated for more than
4 years. The results showed that 28% of these patients
had no tender joints, 24% had no swollen joints, and 21%
had HAQ disability scores of 0 units [20]. Safety data,
which were derived from 1442 patients who had been
receiving etanercept for up to 5 years, showed an overall
low rate of adverse events. The frequency of infections
requiring hospitalization or intravenous antibiotics was
0.04 per patient-year in the total population (3573 patient-
years), equivalent to the rate in placebo groups in con-
trolled trials [20].
The efficacy of etanercept in combination with methotrex-
ate has been evaluated in randomized, double-blind,
placebo-controlled, and open-label extension studies
[21,22]. Weinblatt and colleagues conducted a 6-month
randomized, placebo-controlled, double-blind trial of etan-
ercept 25 mg s.c. twice weekly plus methotrexate in 89
patients with persistently active RA despite at least
6 months of methotrexate therapy at a stable dosage of
10–25 mg/week [21]. The primary efficacy measure was
the percentage of patients who met ACR20 criteria at
24 weeks. Patients treated with the combination experi-
enced rapid and sustained improvement. At 6 months, the
ACR20 criteria were met by 71% of patients treated with
the combination of etanercept and methotrexate but by
only 27% of patients treated with methotrexate plus
placebo (P < 0.001). Furthermore, the ACR50 criteria
were met by 39% of the patients treated with etanercept
plus methotrexate but by only 3% of the patients treated
with methotrexate plus placebo (P < 0.001).
The patients who received etanercept plus methotrexate
had significantly better outcomes according to other
measures of disease activity. At 24 weeks, the ACR70
response criteria were met by 15% of the group receiving
etanercept plus methotrexate, versus 0% of the methotrex-
ate plus placebo group (P = 0.03) [21]. Also at 24 weeks,
patients in the etanercept plus methotrexate group had
median counts of tender joint of 7 versus 17 in the
methotrexate plus placebo group; these were improve-
ments from baseline of 75% and 39%, respectively, in
which patients had a median of 28 tender joints. Further,
those in the etanercept plus methotrexate group had a
median count of 6 swollen joints versus 11 in the
methotrexate plus placebo group; these were improve-
ments from baseline of 78% and 33%, respectively, in
which patients had a median of 18 swollen joints [21]. For
the HAQ data at 24 weeks, there was a 47% improvement
(from median values of 1.5 units at baseline to 0.8 unit at
the end of the study) in the etanercept plus methotrexate
group, and there was a 27% improvement (from median
values of 1.5 units at baseline to 1.1 units at the end of the
study) in the methotrexate plus placebo group [21].
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Adverse events included mild injection-site reactions,
which occurred significantly more often in the etanercept
plus methotrexate group than in the methotrexate plus
placebo group (42% versus 7%, P < 0.001) [21]. Overall,
infection (for example upper respiratory tract infections or
sinusitis) was the most common adverse event, but there
were no significant intergroup differences in incidence or
type of infection [21].
The benefits of etanercept plus methotrexate were further
confirmed in a long-term trial that involved 79 of the 89
patients who had previously participated in the trial dis-
cussed earlier [22]. Of the 79 patients who originally
enrolled, 14 withdrew and 65 patients remained on
therapy for a median of 44 months (maximum 47 months)
[22]. A reduction in the doses of methotrexate and
steroids was allowed after patients had received at least
3 months of etanercept in addition to methotrexate. As
permitted by the protocol, 62% of the 66 patients
assessed at 3 years either reduced (from 17.5 mg/week at
baseline to 11.0 mg/week, a 37% mean reduction;
P < 0.0001) or discontinued their methotrexate dosage,
with 29% of patients discontinuing methotrexate [22].
Among the patients receiving steroids, 3-year data
showed 83% of patients had a reduction (from baseline of
6.4 mg/day to 2.4 mg/day, a 63% mean reduction;
P < 0.0001), with 56% of patients discontinuing steroids
[22]. There was sustained improvement of disease activity,
based on ACR response criteria, in patients treated with
etanercept even though methotrexate and steroid doses
were reduced or their use was discontinued.
Data from 57 patients evaluated for efficacy showed that
77%, 47%, and 23% of patients met ACR20, ACR50,
and ACR70 criteria, respectively, after 3 years of therapy
[22]. These studies indicate that etanercept plus
methotrexate produces clinically significant and long-term
benefits in patients with persistently active RA.
In addition to improving outcomes in patients with chronic
RA, etanercept has been demonstrated to be of benefit in
patients with early RA. In the Early Rheumatoid Arthritis
trial, which consisted of a 1-year blinded phase (n = 632)
[23] and a 1-year open-label extension phase (n = 512)
[24], etanercept 10 or 25 mg s.c. twice weekly was com-
pared with methotrexate (mean dosage 19 mg/week) in
patients with active early RA (mean duration less than
3 years). ACR criteria were employed to assess treatment
efficacy in terms of clinical response. The percentages of
patients in the group assigned to receive etanercept
25 mg who had ACR20, ACR50, and ACR70 responses
were significantly greater than those in the methotrexate
group at most evaluations within the first 6 months
(P < 0.05) but were approximately the same thereafter
[23]. At 12 months, 72% of the patients in the group
assigned to receive etanercept 25 mg had an ACR20
response, as compared with 65% of patients in the
methotrexate group (P = 0.16) [23].
In the same trial, investigators compared the effects of
etanercept and methotrexate on radiographic evidence of
disease progression. Bone erosion and joint-space nar-
rowing were measured radiographically and scored with
the Sharp scale, in which an increase of 1 unit represents
one new erosion or minimal narrowing [23–27]. The Sharp
score is the sum of the erosion scores (based on a six-
point scale of 0 to 5 at 46 joints) and joint-space narrow-
ing scores (based on a five-point scale of 0 to 4 at 42
joints). In this trial the Sharp score ranged from 0 (no
damage) to 398 (severe joint destruction) [23,25–27].
The 12-month data from the blinded phase showed less
radiographic evidence of bone erosion in the etanercept
25 mg group than in the methotrexate group (the mean
increase in erosion score was 0.47 versus 1.03 units,
P = 0.002) [23]. There were no significant differences
between the groups in progression of joint-space narrow-
ing [23]. Patients in the etanercept 25 mg group had
mean Sharp scores of 12.4 ± 15.8, whereas patients in
the methotrexate group had mean Sharp scores of
12.9 ± 13.8 [23,24]. At 6 months the mean total Sharp
scores increased by 0.57 unit in the etanercept 25 mg
group and by 1.06 units in the methotrexate group
(P = 0.001). At 12 months, mean total Sharp scores
increased by 1.00 unit in the etanercept 25 mg group and
by 1.59 units in the methotrexate group (P = 0.11) [23].
Data from the open-label phase showed that, at
24 months, etanercept was more effective than methotrex-
ate in arresting structural damage on the basis of mean
increases in total Sharp scores (1.3 versus 3.2 units,
P = 0.001) and erosion scores (0.7 versus 1.9 units,
P = 0.001) [24]. Effects of etanercept and methotrexate
on joint-space narrowing at the end of 24 months were
comparable (Fig. 1) [24,28].
In terms of physical function, a similar percentage of
patients in the etanercept and methotrexate groups (about
55%) demonstrated an improvement in HAQ score of at
least 0.5 unit at 1 year. The same proportion of etaner-
cept-treated patients (55%) but a lower percentage of
methotrexate-treated patients (37%) maintained improve-
ment for up to 2 years (P < 0.001) (Fig. 2) [24]. As a point
of reference, a change in HAQ score must equal at least
0.22 unit to be considered clinically significant [29].
Another study showing that etanercept led to a sustained
improvement in disease activity, as determined by reduc-
tion in HAQ scores, was conducted by Fleischmann and
colleagues [30]. In this analysis, improvements in HAQ
disability scores over 2 years were compared between
207 patients with early RA (mean duration 1 year) and
563 patients with long-standing (late) RA (mean duration
12 years), who were treated with etanercept 25 mg s.c.
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twice weekly [30]. Mean baseline patient characteristics
for the early RA and late RA groups were similar, including
age (51 versus 53 years), HAQ (1.5 versus 1.6 units),
tender joint count (31 versus 32), swollen joint count (24
versus 26), CRP concentration (3.3 versus 4.4 mg/dl),
and presence of rheumatoid factor (87% versus 81%);
those with early disease had been treated with fewer
DMARDs (0.5 versus 3.3) [30].
Results at 2 years showed that mean HAQ scores declined
in both the early RA (from 1.5 to 0.6 unit) and late RA (from
1.6 to 1.0 unit) groups. A greater percentage of patients
with early disease achieved HAQ scores of 0 units, com-
pared with those who had late disease (29% versus 14%,
P < 0.001) [30]. The study concluded that aggressive
therapy has a greater potential to improve disability, as
measured by HAQ, in patients with early RA than in
patients with more established or late RA who have not
responded satisfactorily to multiple DMARDs [30].
Adalimumab
Adalimumab, also known as D2E7, is a fully human recom-
binant IgG1 anti-TNF monoclonal antibody [31]. Adali-
mumab is available as a preparation that is administered
s.c. every 2 weeks [31]. Studies indicate that adalimumab
is effective and safe as biologic therapy for patients with
RA, with and without methotrexate or in combination with
other DMARDs.
Van de Putte and colleagues studied the efficacy and
safety of adalimumab in a phase III, placebo-controlled,
double-blind, 26-week trial involving 544 patients with RA
who had failed treatment with one or more DMARDs [32].
After a DMARD washout period of 4 weeks, patients were
randomized to one of five groups: adalimumab 20 or
40 mg s.c. weekly or biweekly, or placebo. Baseline demo-
graphics were similar for all groups. Treatment with adali-
mumab produced dose-related and schedule-related
disease improvements measured by ACR20, ACR50, and
ACR70 response criteria, with the monoclonal antibody
demonstrating superiority to placebo at all dosages
(Fig. 3) [32]. Adalimumab was safe and well tolerated,
with the most common adverse events being injection-site
reactions (9.7%), rash (9.4%), and headache (9.4%) [32].
Adalimumab plus methotrexate has been shown to be effi-
cacious in patients who demonstrated a partial response
to methotrexate alone. The Anti-TNF Research Study
Program of the Monoclonal Antibody D2E7 in Patients
With RA (ARMADA) study was a 24-week, randomized,
double-blind, placebo-controlled, dose-ranging trial in
which 271 patients with RA were administered adali-
mumab 20, 40, or 80 mg s.c. every 2 weeks plus
Available online http://arthritis-research.com/content/6/S2/S3
Figure 2
Improvement of at least 0.5 unit in health assessment questionnaire
score at 2 years in patients who had early rheumatoid arthritis and
were given etanercept or methotrexate (MTX). This was an open-label
trial. Reproduced with permission from John Wiley & Sons, Inc. [24]. 
© 2002 American College of Rheumatology
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Figure 3
Increases in ACR20, ACR50, and ACR70 scores in patients with
rheumatoid arthritis who failed previous disease-modifying antirheumatic
drug therapy and were given one of four dosages of adalimumab or
placebo. Adapted with permission from the BMJ Publishing Group [32].
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Changes in total Sharp score, erosion, and joint-space narrowing at 2
years in patients who had early rheumatoid arthritis (RA) and were
given etanercept or methotrexate (MTX). These were the data from the
open-label extension phase of the Early Rheumatoid Arthritis trial [28].
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methotrexate (mean dosage 16.8 mg/week) or placebo
[33,34]. Efficacy measures included the proportion of
patients who attained an ACR20 response at 24 weeks
(primary end point) as well as the proportion of those who
met ACR50 and ACR70 response criteria at the end of
the study [34].
An ACR20 response at 24 weeks was attained by a signif-
icantly greater percentage of patients in the 20, 40, and
80 mg adalimumab plus methotrexate groups (47.8%,
67.2%, and 65.8%, respectively) than in the placebo plus
methotrexate group (14.5%) (P < 0.001) [34]. ACR50
response rates were attained by a significantly greater
percentage of patients in the 20, 40, and 80 mg adali-
mumab groups (31.9%, 55.2%, and 42.5%, respectively)
than in the placebo group (8.1%) (P = 0.003, P < 0.001,
P < 0.001, respectively) [34]. ACR 70 response rates
were attained by a significantly greater percentage of
patients in the 40 and 80 mg adalimumab groups (26.9%
and 19.2%, respectively) than in the placebo group
(4.8%) (P < 0.001 and P < 0.02) [34]. There were also
clinically significant improvements in HAQ and physical
function, where the baseline scores for the 20, 40, 80 mg,
and placebo groups were 1.52, 1.55, 1.55, and
1.64 units, respectively [34]. At 24 weeks, the HAQ data
showed mean reductions in scores of 0.54, 0.62, and
0.59 unit for the adalimumab 20, 40, and 80 mg groups,
respectively, compared with 0.27 for the placebo group
(P = 0.004, P < 0.001, P < 0.001, respectively) [34].
After completing the 6-month (24-week) double-blind
portion of the ARMADA trial, 250 of the original 271
patients entered an open-label extension study that evalu-
ated the efficacy and safety of the combination of adali-
mumab and methotrexate over 12 months [35]. All patients
received adalimumab 40 mg s.c. every other week in com-
bination with methotrexate; 231 of the 250 patients com-
pleted 12 months of treatment [35]. Mean baseline patient
characteristics were as follows: age, 55.1 years; gender,
75.6% female; positivity for rheumatoid factor, 81%; dura-
tion of RA, 12.5 years; number of previous DMARDs used,
3; and methotrexate dosage, 16.8 mg/week [35].
Results showed that when adalimumab was given to
partial responders to methotrexate, clinical efficacy was
sustained throughout 12 months [35]. At 12 months, the
ACR20, ACR50, and ACR70 response rates for the adali-
mumab 40 mg group were 71.2%, 50.8%, and 26.0%,
respectively [35]. With regard to QOL data at 12 months,
the adalimumab 40 mg group showed a decline of 0.6 unit
from baseline, which indicates that the initial response
was maintained for the entire 12 months [34,35].
In a 52-week, double-blind, placebo-controlled trial involv-
ing 619 patients with active RA, treatment with adali-
mumab was shown to inhibit the progression of structural
joint damage in patients with active RA who had an incom-
plete response to methotrexate therapy [36]. Patients
were randomized to receive adalimumab s.c. 40 mg
biweekly or 20 mg weekly, or placebo. Treatment with
methotrexate (mean baseline dosage 16.6 mg/week) was
initiated and continued with no change in dose over the
course of the study. After 1 year there was a significant
response in clinical measures of disease activity in the
adalimumab-treated patients and significant differences in
radiographic end points between the adalimumab-treated
and placebo groups. Mean increases in the Sharp score
for the adalimumab 20 and 40 mg and placebo groups
were 0.8, 0.1, and 2.7, respectively (P ≤ 0.001 versus
placebo) (Fig. 4) [36]. There was a significant decrease in
both joint erosions and joint-space narrowing. Thus, com-
pared with methotrexate alone, treatment with adalimumab
plus methotrexate inhibits the progression of structural
joint disease in patients with RA.
Adalimumab has been shown to be efficacious in patients
who have failed previous DMARD therapy or have demon-
strated incomplete responses to a variety of DMARDs,
including methotrexate. In addition, adalimumab has been
shown to inhibit radiographically evident disease progres-
sion. In each of these studies there was a significant
improvement in physical function and QOL in patients for
up to 1 year. Because the US Food and Drug Administra-
tion (FDA) requires at least 2 years of data showing
improvement, adalimumab has not yet been approved for
this indication [35,36].
Infliximab
Infliximab is a chimeric IgG1-κ monoclonal antibody
against TNF produced by recombinant DNA technology in
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Figure 4
Changes in total Sharp score in patients with active rheumatoid
arthritis who were given one of two dosages of adalimumab or
placebo. Reproduced with permission from John Wiley & Sons, Inc.
[36]. © 2002 American College of Rheumatology
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a continuously perfused cell line [37]. Unlike etanercept,
infliximab does not bind lymphotoxin-α [38]: it binds both
the monomeric and trimeric forms of the inflammatory
cytokine TNF, forming a stable molecular complex with
both molecular species. Infliximab must be administered
by intravenous infusion and has a terminal half-life of
8–10 days. In managing patients with RA, the recom-
mended dose of infliximab is 3 mg/kg initially, followed by
similar doses at weeks 2 and 6, then every 8 weeks there-
after. This regimen can be adjusted by increasing the dose
to 10 mg/kg and/or shortening the intervals between
doses to as often as every 4 weeks to optimize patient
response [37]. As of February 2002, infliximab has been
administered to more than 271,000 patients (data on file,
Centocor, Inc.). Infliximab in combination with methotrex-
ate is the only regimen so far approved by the FDA for
reducing symptoms, inhibiting structural damage, and
improving physical function in patients with moderate-to-
severe RA [37].
The efficacy and safety of infliximab in patients with RA
has been demonstrated in the Anti-TNF Trial in RA With
Concomitant Therapy (ATTRACT) study [39–41] and
several earlier studies [42–46]. ATTRACT was a 2-year,
multicenter, multinational trial of 428 patients with active
RA despite methotrexate therapy. The patients were ran-
domized to one of five regimens: infliximab 3 or 10 mg/kg
intravenously every 4 or 8 weeks, or placebo [39]. All
patients continued to receive a stable dose of methotrex-
ate (median 15 mg/week for at least 6 months; range
10–35 mg/week). At 30 weeks, 50% of patients who
received infliximab 3 mg/kg every 8 weeks met the ACR20
response criteria, compared with 20% of placebo recipi-
ents (P < 0.001) [39]. At 54 weeks, a greater percentage
of patients who received infliximab 3 mg/kg every 8 weeks
met ACR20, ACR50, and ACR70 response criteria than
controls (42% versus 17%, P < 0.001 [ACR20]; 21%
versus 8%, P = 0.027 [ACR50]; and 10% versus 2%,
P = 0.04 [ACR70]) [40]. These improvements in the inflix-
imab-treated patients, compared with the controls, were
sustained for up to 102 weeks (42% versus 16%,
P < 0.001 [ACR20]; 21% versus 6%, P = 0.003
[ACR50]; and 10% versus 1%, P = 0.008, respectively
[ACR70]) [41]. Patients who received the infliximab
10 mg/kg regimens also showed superior improvement in
ACR20, ACR50, and ACR70 response, compared with
controls, for up to 102 weeks [41].
Results from the ATTRACT study indicated that infliximab
halts the progression of structural joint disease and can
even improve some radiographic parameters. At
54 weeks, patients treated with methotrexate plus placebo
demonstrated evidence of increased joint damage, with a
mean change in total Sharp score of 7 units [40]. This
finding is consistent with that of other studies of structural
joint damage in patients receiving DMARDs. However,
patients treated with infliximab showed no evidence of
progressive joint damage and had a mean change in total
Sharp score of 0.6 unit by 54 weeks (P < 0.001) [40]. The
durability of this benefit was confirmed in the 102-week
ATTRACT data (Fig. 5) [39–41].
Two-year follow-up data from the ATTRACT study showed
that infliximab inhibits structural damage in RA patients
with moderately-to-severely active disease as assessed by
the Sharp score, bone erosion scores, and joint-space
narrowing scores [39–41].
In ATTRACT, all regimens (doses/schedules) of infliximab
plus methotrexate showed significantly greater improve-
ment from baseline in HAQ and the Medical Outcomes
Study Short Form Health Survey (SF-36) physical compo-
nent summary score averaged over time through week 54
compared with placebo plus methotrexate [37,40]. In
terms of the median (interquartile range) improvement
from baseline through week 54 in HAQ, was 0.4 (0.1, 0.9)
for the infliximab groups compared with 0.1 (–0.1, 0.5) for
the placebo plus methotrexate group [37]. The favorable
effects on HAQ and SF-36 were sustained through week
102 [37]; all infliximab-treated patients at that time
showed a median improvement in HAQ of 0.3 versus 0.1
for placebo treated patients, P < 0.001 [41].
Conclusion
RA causes significant functional morbidity accompanied
by pain, suffering, and an impaired QOL [47]. The TNF
antagonists represent a significant advance in the therapy
of active RA. The three members of this class – infliximab,
etanercept, and adalimumab – have shown efficacy in
inhibiting joint destruction over various lengths of time,
reducing symptoms, and improving physical function in
Available online http://arthritis-research.com/content/6/S2/S3
Figure 5
Changes in modified Sharp score in patients with active rheumatoid
arthritis despite methotrexate (MTX) therapy who were given MTX
alone or in combination with infliximab (the Anti-Tumor Necrosis Factor
Trial in Rheumatoid Arthritis With Concomitant Therapy [ATTRACT]
study) [39–41].
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patients with RA. However, they have distinct clinical,
pharmacokinetic, and pharmacodynamic properties that
must be considered when selecting a drug for therapy. An
integral component of the decision-making process
regarding choice of therapy is patient preference. Other
factors include published evidence documenting the
overall experience with each drug, the duration of each
trial in which the drugs were studied, the type of statistical
analysis employed, and patient factors such as disease
duration, disease severity at baseline, and the use of previ-
ous and concomitant medications. Careful consideration
of all these clinical variables and appropriate use of the
newer additions to the antirheumatic armamentarium such
as the TNF biologic response modifiers will, it is hoped,
contribute to better outcomes for patients with RA.
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